NCT02342158 2026-04-21
PERMED01
Institut Paoli-Calmettes
Phase NA Completed
Clinical Trials
15 trialsNCT05107219 2026-04-07
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison
Phase 1 Completed
NCT05105100 2026-04-06
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
University of California, San Francisco
Completed
NCT02613962 2026-04-01
MAPPYACTS
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT02971397 2026-03-23
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 1 Completed
NCT02517281 2026-03-20
SKINTARGET
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT05577416 2026-03-18
AB-218-IIT-201
Melbourne Health
Phase EARLY_PHASE1 Completed
NCT00911911 2026-03-13
SPAM
Centre Oscar Lambret
Phase NA Completed
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05371054 2026-02-23
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00897702 2026-01-28
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Memorial Sloan Kettering Cancer Center
Completed